Rong Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rong Deng has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Xiao-Feng Zhu
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
34 shared publications Gong-Kan Feng
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
16 shared publications- Zhi-Ling Li
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
15 shared publications Hai-Liang Zhang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China
13 shared publications- Hai-Liang Zhang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
13 shared publications Dong Yang
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
12 shared publications
Latest Publications
- 21 May 2026
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (11) , 3206-3222
Cell death pathways and targeting therapeutics in cancer therapy
Dysregulated cell death represents a cornerstone of cancer development and therapeutic resistance. This review systematically deciphers the molecular architecture underlying various regulated cell death modalities and their crosstalk. Moving beyond a mere catalog of mechanisms, it critically evaluates the translational landscape of agents that are designed to precisely trigger these pathways. We then critically evaluate the translational strategies that target their key components via diverse agents, from small molecules to PROTACs and nanomedicines. A key focus is the strategic induction of immunogenic cell death to convert tumor cell killing into durable antitumor immunity. This review synthesizes evidence on how distinct death pathways, such as ferroptosis, can be leveraged to remodel the immunosuppressive tumor microenvironment and potentiate immune checkpoint blockade. It further examines the contextual factors that determine the immunogenic outcome of cell death, providing a rationale for combination therapies (e.g., the synergistic effect between ferroptosis inducers and immune checkpoint inhibitors). By integrating mechanistic insights with therapeutic innovations, we provide a framework for developing next-generation therapies that precisely manipulate cell death to overcome treatment resistance and activate immune surveillance. Finally, the review outlines future directions, suggesting the need for the integration of multidisciplinary approaches to discover novel targets, develop selective inducers, and rationally combine cell death modulation with immunotherapy to achieve sustained clinical responses.
- 21 May 2026
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (11) , 3206-3222
Cell death pathways and targeting therapeutics in cancer therapy
Dysregulated cell death represents a cornerstone of cancer development and therapeutic resistance. This review systematically deciphers the molecular architecture underlying various regulated cell death modalities and their crosstalk. Moving beyond a mere catalog of mechanisms, it critically evaluates the translational landscape of agents that are designed to precisely trigger these pathways. We then critically evaluate the translational strategies that target their key components via diverse agents, from small molecules to PROTACs and nanomedicines. A key focus is the strategic induction of immunogenic cell death to convert tumor cell killing into durable antitumor immunity. This review synthesizes evidence on how distinct death pathways, such as ferroptosis, can be leveraged to remodel the immunosuppressive tumor microenvironment and potentiate immune checkpoint blockade. It further examines the contextual factors that determine the immunogenic outcome of cell death, providing a rationale for combination therapies (e.g., the synergistic effect between ferroptosis inducers and immune checkpoint inhibitors). By integrating mechanistic insights with therapeutic innovations, we provide a framework for developing next-generation therapies that precisely manipulate cell death to overcome treatment resistance and activate immune surveillance. Finally, the review outlines future directions, suggesting the need for the integration of multidisciplinary approaches to discover novel targets, develop selective inducers, and rationally combine cell death modulation with immunotherapy to achieve sustained clinical responses.
- Open Access
- 17 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
AAK1 activation-mediated iron trafficking drives ferroptotic cell death
Ferrous iron is necessary for the occurrence of ferroptosis. The molecular mechanisms that maintain iron homeostasis within cells play a crucial role in the regulation of ferroptosis. However, how cells regulate iron uptake during ferroptosis remains unclear. Here, PKCβII is identified as a key kinase mediating transferrin receptor 1 (TFR1) endocytosis through phosphorylation and activation of AP2-associated protein kinase 1 (AAK1) during the ferroptotic process. Mechanistically, activated AAK1 phosphorylates AP2M1, which facilitates the recruitment of clathrin to mediate the endocytosis of TFR1, increasing the levels of both cellular total iron and ferrous iron and thereby promoting ferroptosis. The non-phosphorylatable mutation of AAK1 inhibits ferroptosis and consequently promotes breast tumor growth in vivo. In conclusion, we identify that the PKCβII-AAK1-AP2M1 pathway is a crucial mechanism for the regulation of cellular iron uptake during ferroptosis, which is correlated with the prognosis of breast cancer patients and presents a potential target for cancer therapy.
- 17 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAAK1 activation-mediated iron trafficking drives ferroptotic cell death
Ferrous iron is necessary for the occurrence of ferroptosis. The molecular mechanisms that maintain iron homeostasis within cells play a crucial role in the regulation of ferroptosis. However, how cells regulate iron uptake during ferroptosis remains unclear. Here, PKCβII is identified as a key kinase mediating transferrin receptor 1 (TFR1) endocytosis through phosphorylation and activation of AP2-associated protein kinase 1 (AAK1) during the ferroptotic process. Mechanistically, activated AAK1 phosphorylates AP2M1, which facilitates the recruitment of clathrin to mediate the endocytosis of TFR1, increasing the levels of both cellular total iron and ferrous iron and thereby promoting ferroptosis. The non-phosphorylatable mutation of AAK1 inhibits ferroptosis and consequently promotes breast tumor growth in vivo. In conclusion, we identify that the PKCβII-AAK1-AP2M1 pathway is a crucial mechanism for the regulation of cellular iron uptake during ferroptosis, which is correlated with the prognosis of breast cancer patients and presents a potential target for cancer therapy.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Antibodies used in Flow cytometry analysis
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Antibodies used in Flow cytometry analysis
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S2. Targeting mutant NRAS activates the STING signaling. A-B. The indicated NRAS mutant cells and wild type NRAS cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (A) and qRT-PCR analysis (n = 3 biological independent samples) (B). C-D. The indicated NRAS wild type cells A2058, A375 were transiently transfected with site-specific siRNAs targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples) (C) and western blot analysis (D). E. The schematic overview of RNA-seq in HT1080 cell lines. F-G. HT1080, ME4405, SNU719 cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (F) and qRT-PCR analysis (n = 3 biological independent samples) (G). H. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). I. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were treated with 200ng/mL poly(dA:dT) for 18h. The cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). Error bars represent mean ± SD. The p-values in B and G were determined by a two-tailed unpaired Student’s t test.The p-values in C and H-I were calculated using one-way ANOVA followed by Dunnett's multiple comparisons test, **p < 0.01. Data in A-D, F-G are representative of three independent experiments. Data in H-I are representative of two independent experiments.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S2. Targeting mutant NRAS activates the STING signaling. A-B. The indicated NRAS mutant cells and wild type NRAS cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (A) and qRT-PCR analysis (n = 3 biological independent samples) (B). C-D. The indicated NRAS wild type cells A2058, A375 were transiently transfected with site-specific siRNAs targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples) (C) and western blot analysis (D). E. The schematic overview of RNA-seq in HT1080 cell lines. F-G. HT1080, ME4405, SNU719 cells were transiently transfected with specific siRNAs targeting NRAS, then cells were harvested for western blot analysis (F) and qRT-PCR analysis (n = 3 biological independent samples) (G). H. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). I. HT1080, ME4405 cells were transiently transfected with specific siRNAs with or without 2’-O-Me modification (siQ61K-“GU” or siQ61R-“GU”) targeting NRAS, then cells were treated with 200ng/mL poly(dA:dT) for 18h. The cells were harvested for qRT-PCR analysis (n = 3 biological independent samples). Error bars represent mean ± SD. The p-values in B and G were determined by a two-tailed unpaired Student’s t test.The p-values in C and H-I were calculated using one-way ANOVA followed by Dunnett's multiple comparisons test, **p < 0.01. Data in A-D, F-G are representative of three independent experiments. Data in H-I are representative of two independent experiments.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S1 The clinical significance of the interferon alpha response in NRAS wild-type melanoma patients in the TCGA cohort. Kaplan-Meier analyses of OS, DSS and PFS based on enrichment score of the interferon alpha response for patients with NRAS wild-type melanoma. The data were retrieved from TCGA database.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S1 The clinical significance of the interferon alpha response in NRAS wild-type melanoma patients in the TCGA cohort. Kaplan-Meier analyses of OS, DSS and PFS based on enrichment score of the interferon alpha response for patients with NRAS wild-type melanoma. The data were retrieved from TCGA database.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
The source data related to this study are provided in the Supplementary Source Data file.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
The source data related to this study are provided in the Supplementary Source Data file.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Antibodies used in immunoblot and immunoprecipitation
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Antibodies used in immunoblot and immunoprecipitation
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Clinical characteristics of melanoma patients in TCGA
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Clinical characteristics of melanoma patients in TCGA
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S3. The suppression of cGAS-STING pathway in NRAS mutant cells mediates immune escape. A. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with poly(dA:dT). B. Immunoblot in NCI-H1299 cells expressing sgRNA targeting STING. C. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with HT-DNA. D-E. Flow cytometry measuring the cytotoxicity of PBMCs that killing the cancer cells pre-treated with poly(dA:dT) (D) and HT-DNA(E). F. FACS analysis of CD8+T, NK1.1+, and IFNγ+ or Granzyme B+ in CD8+ T cell populations and NK cell populations from the isolated TILs. Representative dot plots from a representative mouse for each group.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Reactivating cGAS–STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors
Supplementary Fig. S3. The suppression of cGAS-STING pathway in NRAS mutant cells mediates immune escape. A. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with poly(dA:dT). B. Immunoblot in NCI-H1299 cells expressing sgRNA targeting STING. C. Flow cytometry measuring the DCs mature markers (MHC II and CD86), when co-cultured with the indicated tumor cells pre-treated with HT-DNA. D-E. Flow cytometry measuring the cytotoxicity of PBMCs that killing the cancer cells pre-treated with poly(dA:dT) (D) and HT-DNA(E). F. FACS analysis of CD8+T, NK1.1+, and IFNγ+ or Granzyme B+ in CD8+ T cell populations and NK cell populations from the isolated TILs. Representative dot plots from a representative mouse for each group.